Genotype Ser413/Ser of PAI-2 polymorphism Ser413/Cys is associated with anti-phospholipid syndrome and systemic lupus erythematosus in a familial case: Comparison with healthy controls

Scandinavian Journal of Rheumatology

Volumn 36, Issue 3, 2007, Pages 206-210

  Mercado, M Vázquez Del ^a,c   Garcia Cobian T A ^a   Valle, J F Mũoz ^a   Torres Carrillo, N ^a   Martin Marquez B T ^a   Arana Argaez, V E ^a   Best Aguilera, C R ^b   Martinez Garcia E A ^a   Petri, M H ^a   Nunez Atahualpa L ^a   Delgado Rizo, V ^a  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b West General Hospital   (Mexico)

^c Edificio P ^*  (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; SERINE;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FAMILIAL DISEASE; FAMILY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; INHERITANCE; MEXICO; PEDIGREE ANALYSIS; POLYMERASE CHAIN REACTION; POPULATION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIPHOSPHOLIPID SYNDROME; CHILD; FEMALE; GENOTYPE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PEDIGREE; PLASMINOGEN ACTIVATOR INHIBITOR 2; POLYMORPHISM, GENETIC;

EID: 34547493556     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740601089648     Document Type: Article

References (20)

1. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752-63.
2. Mackworth-Young CG. Antiphospholipid syndrome: multiple mechanisms. Clin Exp Immunol 2004;136:393-401.
3. Alarcon-Segovia D, Cabral AR. The concept and classification of antiphospholipid/cofactor syndromes. Lupus 1996;5:364-7.
4. Marai I, Zandman-Goddard G, Shoenfeld Y. The systemic nature of the antiphospholipid syndrome. Scand J Rheumatol 2004;33:365-72.
5. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
6. Perdriger A, Werner-Leyval S, Rollot-Elamrani K. The genetic basis for systemic lupus erythematosus. Joint Bone Spine 2003;70:103-8.
7. Salazar-Paramo M, Garcia de la Torre I, Fritzler MJ, Loyau S, Angles-Cano E. Antibodies to fibrin-bound tissue-type plasminogen activator in systemic lupus erythematosus are associated with Raynaud's phenomenon and thrombosis. Lupus 1996;5:275-8.
8. Priori R, Medda E, Conti F, Cassara EA, Danieli MG, Gerli R, et al. Familial autoimmunity as a risk factor for systemic lupus erythematosus and vice versa: a case-control study. Lupus 2003;12:735-40.
9. Kohler HP GP. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000;342:1792-801.
10. Foy CA, Grant PJ. PCR-RFLP detection of PAI-2 gene variants: prevalence in ethnic groups and disease relationship in patients undergoing coronary angiography. Thromb Haemost 1997;77:955-8.
11. Yu H, Maurer F, Medcalf RL. Plasminogen activator inhibitor type 2: a regulator of monocyte proliferation and differentiation. Blood 2002;99:2810-18.
12. Buyru N, Altinisik J, Gurel CB, Ulutin T. PCR-RFLP detection of PAI-2 variants in myocardial infarction. Clin Appl Thromb Hemost 2003;9:333-6.
13. Bechtel MJ, Schaefer BM, Kramer MD. Plasminogen activator inhibitor type-2 in the lesional epidermis of lupus erythematosus. Br J Dermatol 1996;134:411-19.
14. Patrassi GM, Sartori MT, Viero ML, Scarano L, Boscaro M, Girolami A. The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state. Blood Coagul Fibrinolysis 1992;3:789-93.
15. Tassies D, Espinosa G, Munoz-Rodriguez FJ, Freire C, Cervera R, Monteagudo J, et al. The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. Arthritis Rheum 2000;43:2349-58.
16. Eroglu GE, Kohler PF. Familial systemic lupus erythematosus: the role of genetic and environmental factors. Ann Rheum Dis 2002;61:29-31.
17. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;11;16:1215.
18. Margaglione M, Grandone E, Di Minno G. Plasma predictors of ischemic complications of atherosclerosis: open issues. Biomed Pharmacother 1993;47:445-9.
19. Ruiz-Quezada S, Vazquez-Del Mercado M, Parra-Rojas I, Rangel-Villalobos H, Best-Aguilera C, Sanchez-Orozco LV, et al. Genotype and allele frequency of PAI-1 promoter polymorphism in healthy subjects from the west of Mexico. Association with biochemical and hematological parameters. Ann Genet 2004;47:155-62.
20. Akar N YE, Akar E, Avcu F, Yalcin A, Cin S. Effect of plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish deep vein thrombotic patients with and without FV1691 G-A. Thromb Res 2000;97:227-30.